Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Ovarian Neoplasms

Free Subscription Articles published in Br J Cancer Retrieve available abstracts of 53 articles: HTML format

Single Articles

October 2025
1. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
   Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
   Br J Cancer. 2025;133:874-885.
   PubMed     Abstract available
   
   
   September 2025
2. WU R, Arendse KD, Hamdani T, Walter FM, et al
   Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care.
   Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03166.
   PubMed     Abstract available
   
   
   
3. ARENDSE KD, Walter FM, Abel G, Rous B, et al
   CA125 and age-based models for ovarian cancer detection in primary care: a population-based external validation study.
   Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03165.
   PubMed     Abstract available
   
   
   August 2025
4. MULUGETA A, Stacey D, Lumsden AL, Madakkatel I, et al
   Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis.
   Br J Cancer. 2025 Aug 28. doi: 10.1038/s41416-025-03143.
   PubMed     Abstract available
   
   
   July 2025
5. SOOI K, Tan TZ, Kim JW, Lee JY, et al
   A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
   Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03090.
   PubMed     Abstract available
   
   
   
6. FICORELLA L, Yang X, Mavaddat N, Carver T, et al
   Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.
   Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117.
   PubMed     Abstract available
   
   
   June 2025
7. STANGE C, Dreyer TF, Riedel M, Elsen F, et al
   PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer.
   Br J Cancer. 2025 Jun 27. doi: 10.1038/s41416-025-03076.
   PubMed     Abstract available
   
   
   
8. LIU Y, Chen Z, Duan Y, Shao Z, et al
   Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the malignant progression of ovarian cancer.
   Br J Cancer. 2025 Jun 24. doi: 10.1038/s41416-025-03079.
   PubMed     Abstract available
   
   
   
9. NARAYANAN B, Buddenkotte T, Smith H, Shah M, et al
   Growth kinetics of high-grade serous ovarian cancer: implications for early detection.
   Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03082.
   PubMed     Abstract available
   
   
   April 2025
10. TREWIN-NYBRATEN CB, Leithe S, Paulsen T, Langseth H, et al
    Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
    Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03018.
    PubMed     Abstract available
    
    
    
11. LAGA T, Van Rompuy AS, Busschaert P, Marquina G, et al
    Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.
    Br J Cancer. 2025 Apr 23. doi: 10.1038/s41416-025-03012.
    PubMed     Abstract available
    
    
    March 2025
12. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.
    Br J Cancer. 2025 Mar 17. doi: 10.1038/s41416-025-02966.
    PubMed     Abstract available
    
    
    December 2024
13. MERRITT MA, Abe SK, Islam MR, Rahman MS, et al
    Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium.
    Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02924.
    PubMed     Abstract available
    
    
    
14. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    PubMed     Abstract available
    
    
    
15. XU Q, Kowalski J
    Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer.
    Br J Cancer. 2024;131:1825-1832.
    PubMed     Abstract available
    
    
    November 2024
16. MORGAN RD, Wang X, Barnes BM, Spurgeon L, et al
    Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
    Br J Cancer. 2024 Nov 16. doi: 10.1038/s41416-024-02874.
    PubMed     Abstract available
    
    
    
17. TAN R, Wen M, Yang W, Zhan D, et al
    Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets.
    Br J Cancer. 2024 Nov 15. doi: 10.1038/s41416-024-02894.
    PubMed     Abstract available
    
    
    
18. ZAHID MU, Waguespack M, Harman RC, Kercher EM, et al
    Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study.
    Br J Cancer. 2024;131:1378-1386.
    PubMed     Abstract available
    
    
    October 2024
19. SUN Y, Yin Z, Li S, Wu L, et al
    Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
    Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02863.
    PubMed     Abstract available
    
    
    September 2024
20. YANG X, Wu Y, Ficorella L, Wilcox N, et al
    Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.
    Br J Cancer. 2024 Sep 18. doi: 10.1038/s41416-024-02851.
    PubMed     Abstract available
    
    
    
21. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    PubMed     Abstract available
    
    
    
22. SMITH HL, Willmore E, Prendergast L, Curtin NJ, et al
    ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Br J Cancer. 2024;131:905-917.
    PubMed     Abstract available
    
    
    August 2024
23. TAKAMATSU S, Hillman RT, Yoshihara K, Baba T, et al
    Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02837.
    PubMed     Abstract available
    
    
    
24. ZHUO L, Meng F, Sun K, Zhou M, et al
    Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis.
    Br J Cancer. 2024 Aug 2. doi: 10.1038/s41416-024-02803.
    PubMed     Abstract available
    
    
    July 2024
25. NAGLE CM, Ibiebele TI, Bandera EV, Cramer D, et al
    Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2024 Jul 18. doi: 10.1038/s41416-024-02792.
    PubMed     Abstract available
    
    
    June 2024
26. ARONSON SL, Walker C, Thijssen B, van de Vijver KK, et al
    Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02731.
    PubMed     Abstract available
    
    
    
27. QIU L, Li R, Wang Y, Lu Z, et al
    PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex.
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02749.
    PubMed     Abstract available
    
    
    May 2024
28. KENKHUIS MF, Stelten S, Hartman YA, Brouwer CG, et al
    Effects of a combined exercise and dietary intervention on body composition, physical functioning and fatigue in patients with ovarian cancer: results of the PADOVA trial.
    Br J Cancer. 2024 May 8. doi: 10.1038/s41416-024-02694.
    PubMed     Abstract available
    
    
    
29. HERMAN L, Amo A, Legois B, Di Carlo C, et al
    A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp.
    Br J Cancer. 2024;130:1453-1462.
    PubMed     Abstract available
    
    
    
30. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    PubMed     Abstract available
    
    
    April 2024
31. DHAR C, Ramachandran P, Xu G, Pickering C, et al
    Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
    PubMed     Abstract available
    
    
    
32. KMENT J, Newsted D, Young S, Vermeulen MC, et al
    Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
    Br J Cancer. 2024 Apr 15. doi: 10.1038/s41416-024-02677.
    PubMed     Abstract available
    
    
    February 2024
33. ZHENG G, Faber MT, Wang J, Baandrup L, et al
    Low-dose aspirin use and risk of ovarian cancer: a combined analysis from two nationwide studies in Denmark and Sweden.
    Br J Cancer. 2024 Feb 12. doi: 10.1038/s41416-024-02609.
    PubMed     Abstract available
    
    
    
34. MONJE N, Dragomir MP, Sinn BV, Hoffmann I, et al
    AHRR and SFRP2 in primary versus recurrent high-grade serous ovarian carcinoma and their prognostic implication.
    Br J Cancer. 2024 Feb 9. doi: 10.1038/s41416-023-02550.
    PubMed     Abstract available
    
    
    January 2024
35. NICUM S, McGregor N, Austin R, Collins L, et al
    Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
    Br J Cancer. 2024 Jan 20. doi: 10.1038/s41416-023-02567.
    PubMed     Abstract available
    
    
    
36. LANDOLFO C, Ceusters J, Valentin L, Froyman W, et al
    Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery.
    Br J Cancer. 2024 Jan 19. doi: 10.1038/s41416-024-02578.
    PubMed     Abstract available
    
    
    
37. YOUNG HAN C, Bedia JS, Yang WL, Hawley SJ, et al
    Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
    Br J Cancer. 2024 Jan 9. doi: 10.1038/s41416-023-02560.
    PubMed     Abstract available
    
    
    December 2023
38. ZEBIC DS, Tjokrowidjaja A, Francis KE, Friedlander M, et al
    Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02528.
    PubMed     Abstract available
    
    
    
39. HERRINGTON CS, Oswald AJ, Stillie LJ, Croy I, et al
    Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02508.
    PubMed     Abstract available
    
    
    
40. POSTEL-VINAY S, Coves J, Texier M, Aldea M, et al
    Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
    Br J Cancer. 2023 Dec 14. doi: 10.1038/s41416-023-02514.
    PubMed     Abstract available
    
    
    
41. ARTER ZL, Desmond D, Berenberg JL, Killeen JL, et al
    Epithelial ovarian cancer survival by race and ethnicity in an equal-access healthcare population.
    Br J Cancer. 2023 Dec 6. doi: 10.1038/s41416-023-02471.
    PubMed     Abstract available
    
    
    October 2023
42. PETRICK JL, Joslin CE, Johnson CE, Camacho TF, et al
    Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium.
    Br J Cancer. 2023 Oct 21. doi: 10.1038/s41416-023-02407.
    PubMed     Abstract available
    
    
    
43. PARK J, Kim JC, Lee M, Lee J, et al
    Frequency of peripheral PD-1(+)regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer.
    Br J Cancer. 2023 Oct 11. doi: 10.1038/s41416-023-02455.
    PubMed     Abstract available
    
    
    
44. BHAMIDIPATI D, Haro-Silerio JI, Yap TA, Ngoi N, et al
    PARP inhibitors: enhancing efficacy through rational combinations.
    Br J Cancer. 2023;129:904-916.
    PubMed     Abstract available
    
    
    August 2023
45. CHOI JA, Kim H, Kwon H, Lee EH, et al
    Ascitic autotaxin as a potential prognostic, diagnostic, and therapeutic target for epithelial ovarian cancer.
    Br J Cancer. 2023 Aug 18. doi: 10.1038/s41416-023-02355.
    PubMed     Abstract available
    
    
    
46. JOHNSON CE, Alberg AJ, Bandera EV, Peres LC, et al
    Association of inflammation-related exposures and ovarian cancer survival in a multi-site cohort study of Black women.
    Br J Cancer. 2023 Aug 3. doi: 10.1038/s41416-023-02385.
    PubMed     Abstract available
    
    
    July 2023
47. LEE JE, Kim KT, Shin SJ, Cheong JH, et al
    Genomic and evolutionary characteristics of metastatic gastric cancer by routes.
    Br J Cancer. 2023 Jul 8. doi: 10.1038/s41416-023-02338.
    PubMed     Abstract available
    
    
    June 2023
48. YANG Z, Wang XL, Bai R, Liu WY, et al
    Retraction Note: miR-23a promotes IKKalpha expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells.
    Br J Cancer. 2023 Jun 26. doi: 10.1038/s41416-023-02328.
    PubMed    
    
    
    April 2023
49. QUINTELA M, James DW, Garcia J, Edwards K, et al
    In silico enhancer mining reveals SNS-032 and EHMT2 inhibitors as therapeutic candidates in high-grade serous ovarian cancer.
    Br J Cancer. 2023 Apr 29. doi: 10.1038/s41416-023-02274.
    PubMed     Abstract available
    
    
    
50. O'MAHONY DG, Ramus SJ, Southey MC, Meagher NS, et al
    Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
    Br J Cancer. 2023 Apr 19. doi: 10.1038/s41416-023-02263.
    PubMed     Abstract available
    
    
    
51. MARTIN AL, Colin-Leitzinger CM, Sinha SK, Chern JY, et al
    Impact of obesity on chemotherapy dosing of carboplatin and survival of women with ovarian cancer.
    Br J Cancer. 2023 Apr 6. doi: 10.1038/s41416-023-02259.
    PubMed     Abstract available
    
    
    March 2023
52. LONG X, Lu H, Cai MC, Zang J, et al
    APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis.
    Br J Cancer. 2023 Mar 30. doi: 10.1038/s41416-023-02239.
    PubMed     Abstract available
    
    
    January 2023
53. TAKAMATSU S, Yoshihara K, Baba T, Shimada M, et al
    Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.
    Br J Cancer. 2023 Jan 2. doi: 10.1038/s41416-022-02122.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge.